- Home
- CRIS vs CMMB Comparison
CRIS vs CMMB Comparison
Compare CRIS & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | CMMB |
|---|---|---|
| Founded | 2000 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 13.8M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRIS | CMMB |
|---|---|---|
| Price | $1.05 | $1.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $16.50 | ★ $26.50 |
| AVG Volume (30 Days) | ★ 119.8K | 97.8K |
| Earning Date | 11-06-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,650,000.00 | N/A |
| Revenue This Year | $6.13 | N/A |
| Revenue Next Year | $8.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.56 | N/A |
| 52 Week Low | $1.02 | $1.73 |
| 52 Week High | $4.50 | $9.84 |
Technical Indicators
Market Signals| Indicator | CRIS | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 35.22 | 28.76 |
| Support Level | $1.14 | $1.73 |
| Resistance Level | $1.41 | $2.24 |
| Average True Range (ATR) | 0.08 | 0.27 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 7.50 | 14.42 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.